Impact of Poor Tolerance and Discontinuation of the Dexamethasone during Treatment with Lenalidomide-Dexamethasone in Relapsed and Refractory Multiple Myeloma
Stéphanie Guidez(Inserm), Xavier Leleu(Inserm), Bertrand Arnulf(Université Paris Cité), Thierry Façon(Université de Lille), Cécile Fohrer(Hôpital d'Hautepierre), Murielle Roussel(Centre Hospitalier Universitaire de Limoges), Guillemette Fouquet(Centre Hospitalier Universitaire de Lille), Lionel Karlin(Hôpital Lyon Sud), Charles Lancesseur(Centre Hospitalier Universitaire de Caen Normandie), Margaret Macro(Hôpital Cochin), Denis Caillot, Morgane Nudel(Centre Hospitalier Universitaire de Lille), Benjamin Hébraud(Institut universitaire du cancer de Toulouse Oncopole), Marie Lorraine Chrétien(CHU Dijon Bourgogne), Cyrille Hulin(Centre Hospitalier Régional et Universitaire de Nancy), Eileen M. Boyle(BMW (Germany)), Olivier Decaux(Hôpital Pontchaillou), Hélène Demarquette(Ikerbasque)
Cited by 0
Related Papers
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
|Nature Communications|2014|906
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719